Publicacions en col·laboració amb investigadors/es de Fundación Jiménez Díaz (11)

2023

  1. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain

    Annals of Hematology, Vol. 102, Núm. 2, pp. 447-456

  2. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

    Annals of Hematology, Vol. 101, Núm. 10, pp. 2263-2270

2021

  1. Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia

    British Journal of Haematology, Vol. 192, Núm. 6, pp. 988-996

  2. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

    Blood Cancer Journal

2020

  1. Chronic myelogenous leukemia and myeloproliferative disorders in older adults

    Geriatric Oncology (Springer International Publishing), pp. 535-547

  2. Early Prediction of Subsequent Molecular Response to Nilotinib in Patients with Chronic Myeloid Leukemia: Comparison of the Quantification of BCR-ABL1 Ratios Using ABL1 or GUSB Control Genes

    Journal of Molecular Diagnostics, Vol. 22, Núm. 10, pp. 1217-1224

2019

  1. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients

    Annals of Hematology, Vol. 98, Núm. 2, pp. 321-330

2018

  1. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients

    Blood Cancer Journal, Vol. 8, Núm. 10

2017

  1. A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia

    PLoS ONE, Vol. 12, Núm. 3

2015

  1. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program

    American Journal of Hematology, Vol. 90, Núm. 5, pp. 429-433